The most commonly reported side effects of potassium phosphate monobasic include fatigue, diarrhoea, and dyspnoea, based on 59,147 FDA adverse event reports from 2004 to 2025. 4.8% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for potassium phosphate monobasic.
These are voluntary reports and do not establish that potassium phosphate monobasic caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside potassium phosphate monobasic. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
64.2% of potassium phosphate monobasic adverse event reports involve female patients and 31.1% involve male patients. The largest age group is elderly at 56%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking potassium phosphate monobasic when the adverse event was reported.
Showing 15 of 583 indications
Potassium Phosphate Monobasic is sold under the brand name Potassium Phosphates In 0.9% Sodium Chloride.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.